Last update June 14, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
チアプリド塩酸塩 is Tiapride in Japanese.
Is written in other languages:チアプリド塩酸塩 belongs to these groups or families:
Main tradenames from several countries containing チアプリド塩酸塩 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 75 | % |
Molecular weight | 365 | daltons |
Protein Binding | ≈ 0 | % |
VD | 1.43 | l/Kg |
pKa | 13.23 | - |
Tmax | 1 -2 | hours |
T½ | 3 - 4 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Tiapride is a substituted benzamide with general properties similar to those of sulpiride. It is used in behavioral disorders, in dyskinesias (chorea), anxiety in the elderly, alcohol withdrawal syndrome, negative symptoms of psychosis and as an analgesic. Oral administration in 2 to 3 daily doses; Also intramuscularly or intravenously.
Since the last update we have not found published data on its excretion in breastmilk.
Its almost null binding to plasmatic proteins makes it likely that significant amounts will pass into breast milk; its large volume of distribution would make it difficult.
It may cause hyperprolactinemia and galactorrhea. (Greil 1985, Le Bigot 1982)
It may cause drowsiness.
See below the information of this related product: